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Cutaneous and renal glomerular vasculopathy (CRGV) is a rare disease affecting
dogs, with a recent apparent increase in prevalence since 2012 in the UK. This
disease is characterized by a vasculopathy affecting small vessels of the kidney and
skin, leading to thrombotic microangiopathy. The underlying etiology remains unknown
although clinicopathological and histological findings resemble features of certain forms
of thrombotic microangiopathy in people, for which plasma exchange (PEX) is considered
an important component of therapy. The objective of the present study is to describe the
use of PEX as adjunctive treatment in dogs diagnosed with CRGV. A retrospective review
of dogs diagnosed with CRGV between 2014 and 2016 treated with PEX was performed.
Clinical records were reviewed and data relating to signalment, diagnostic tests and
management strategies were summarized. Information and complications relating to
PEX were recorded. Six dogs were diagnosed with CRGV (n = 2 ante-mortem, n = 4
post-mortem) and underwent PEX as part of their therapy. All dogs had cutaneous lesions
and were azotemic with oliguria or anuria. All dogs underwent at least one PEX cycle;
one dog had a single cycle PEX, three dogs two cycles PEX, and two dogs had one cycle
PEX and one cycle of prolonged intermittent renal replacement treatment. Complications
seen during PEX therapy included hypothermia (n = 4), tachycardia (n = 2), hypotension
(n = 2), and hypocalcemia (n = 6). Two dogs survived to discharge, the remaining four
dogs were euthanized. The positive outcome in two dogs treated with PEX despite the
reported high mortality rate once acute kidney injury with oliguria/anuria occurs does
not confirm success of this treatment. However, survival in two dogs that were initially
oligoanuric highlights that further consideration and evaluation of PEX for this patient
group is warranted for this specific disease. Additional studies are urgently needed
to identify the underlying etiology of CRGV before more targeted therapies can be
developed. Based on our findings, further evaluation of the role of PEX in this specific
disease are warranted.
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INTRODUCTION
Thrombotic microangiopathy (TMA) syndromes have been
described in people and in dogs with the hallmark of
these conditions being endothelial damage and subsequent
vascular occlusion leading to anemia, thrombocytopenia and
organ dysfunction (1). Thrombotic microangiopathy has been
described in isolated cases and was the presumed cause of an
outbreak affecting over 100 greyhounds in the USA (2) following
histopathological examination of cutaneous and renal tissue in 10
of these cases. One of the most common conditions associated
with TMA in dogs has been described as cutaneous and renal
glomerular vasculopathy (CRGV) (2–5). This is a serious and
life-threatening condition with no underlying cause yet identified
with limited therapeutic options available.
A recent retrospective study in dogs in the UK described both
the clinical and histopathological findings associated with this
condition in detail; patients typically presented with ulcerative
skin lesions affecting the distal limbs, variable degrees of anemia,
thrombocytopenia, and developed acute kidney injury (AKI) and
kidney failure within 7–10 days (5).
In people, TMA can be caused by two main diseases:
Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic
Uremic Syndrome (HUS). Both TTP and HUS can manifest
in acquired and congenital forms (1). Hemolytic Uremic
Syndrome can be categorized as infection-associated HUS (E. coli
Shiga toxin), atypical HUS (aHUS; dysregulation of alternative
complement pathway), secondary HUS (e.g., collagen vascular
disease, drug-associated, autoimmune diseases, disseminated
malignancy and malignant hypertension) and idiopathic HUS
(1, 6, 7) although contributing factors in affected individuals
across these forms may overlap. The features of TMA can also be
identified in patients with disseminated vascular coagulation (7).
Thrombotic thrombocytopenic purpura has been related to the
metalloprotease enzyme, ADAMTS13 deficiency. This protease
is involved in the cleavage of ultra-large von Willebrand factor
into smaller subunits. The most common cause of reduced levels
of ADAMTS13 is its binding to IgG autoantibody present in TTP
(8).
In the pathogenesis of TMA syndromes, the presence of
specific circulating blood constituents is common, offering
potential targets for therapy. Therapeutic plasma exchange
(PEX), also known as plasmapheresis or total plasma exchange,
consists of the removal of the patient’s plasma (and its
constituent components) via centrifugation or filtration through
an extracorporeal circuit and its replacement with allogenic
plasma transfusion, human serum albumin, isotonic crystalloids
or synthetic colloids (9).
Therefore, the goal of PEX in this context is to
remove molecules responsible for the pathogenesis of the
Abbreviations:AKI, Acute Kidney Injury; aHUS, atypical HUS; CRGV, Cutaneous
and Renal Glomerular Vasculopathy; HUS, Hemolytic Uremic Syndrome; MAT,
Macroscopic Agglutination Test; pRBC, Packed Red Blood Cells; PEX, Plasma
Exchange; PIRRT, prolonged intermittent renal replacement treatment; PV,
plasma volume; RI, reference interval; TMA, Thrombotic Microangiopathy; TPE,
Total Plasmapheresis; TTP, Thrombotic Thrombocytopenic Purpura; UOP, urine
output; UPC, urine protein creatinine ratio.
microangiopathy, such as autoantibody-inhibited ADAMTS13
in TTP, or complement regulators [e.g., factor H (CFH) and
membrane cofactor protein (MCP)], in aHUS (8). Plasma
exchange has been shown to increase survival from 10 to
78% in people with TTP (1). Based on the American Society
for apheresis’ guidelines, PEX therapy is considered a first-
line therapy (Category I) in people with clinicopathological
signs, complement-mediated TMA (Factor H autoantibodies),
drug-associated TMA (e.g., ticlopidine) and TTP (7, 8, 10, 11).
People with HUS often have a more severe degree of
kidney injury compared to TTP, therefore PEX is recommended
alongside early treatment with renal replacement therapy in the
attempt to halt progression to irreversible kidney injury (8).
The clinical use of PEX in dogs has been previously described
in several conditions such as systemic lupus erythematosus
(12), hyperviscosity syndrome (13, 14), myasthenia gravis
(15), immune-mediated hemolytic anemia (16), treatment of
meloxicam and ibuprofen overdose (17, 18), and kernicterus
(19). The management of patients with clinically suspected
CRGV in the UK has been challenging given that there is
no known underlying etiology and there is severe morbidity
associated with the condition. In a recent report of dogs
with suspected CRGV (5), all dogs that developed azotemia
and oliguria/anuria died or were euthanized regardless of the
treatment they received. Currently, a definitive diagnosis of
canine CRGV is only made at post-mortem examination by
renal histopathology and no therapy has been shown to prevent
progression of the disease or improve outcome (5). In the
absence of renal histopathological confirmation, compatible
clinical presentation, clinicopathological changes and dermal
histopathology are strongly supportive of a diagnosis of CRGV.
Based on the potential similarity in pathophysiology between
canine CRGV and conditions in people such as TTP or aHUS,
PEX was hypothesized as a novel therapeutic option for affected
dogs (5). The aim of this study was to retrospectively describe the
use of PEX, report associated complications and outcome in six
dogs clinically diagnosed with CRGV.
MATERIALS AND METHODS
Dogs presented to the Queen Mother Hospital for Small
Animals (QMHA) between January 2014 and December 2016
and diagnosed with CRGV were included in the study. Eligible
dogs were identified by searching the hospital medical database
using the terms “CRGV” and “plasmapheresis.” Inclusion criteria
were dogs clinically diagnosed with CRGV receiving at least
one cycle of PEX. A diagnosis of CRGV was made on the
basis of renal histopathology if post-mortem examination had
been performed or on the basis of compatible historical data,
clinical signs including ulcerative skin lesions, hematological and
biochemical findings and dermal histopathology compatible with
the description provided by Holm et al. 2015 (5). Cases with an
uncertain diagnosis of CRGV were excluded.
Medical records were reviewed in order to collect the
following data for each patient: signalment, clinical signs,
physical examination abnormalities, hematology using ADVIA
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212Oi R© (Siemens Healthcare, UK), serum biochemistry using
iLab 600 R© (Instrumentation Laboratory, UK), activated partial
thromboplastin time, prothrombin time using coagulation
profile, ST Hemostasis Analyzer (Diagnostica Stago Ltd.,
UK) or IDEXX Coag DxTM (IDEXX Laboratories, UK),
urinalysis (including dipstick, urine protein creatinine ratio
(UPC), sediment analysis and culture), imaging (abdominal
ultrasonography, thoracic radiography), infectious disease
including detection for Leptospirosis antibodies by using
microscopic agglutination test, (Leptospirosis MAT R©; IDEXX
Laboratories, UK), Leptospirosis polymerase chain reaction
test to detect Leptospira spp. (Leptospira spp. RealPCR
Test R© IDEXX Laboratories, UK) and test for tick-borne
diseases by using SNAP R© 4Dx R© (IDEXX Laboratories, UK).
Histopathological data from biopsies of skin lesions or post-
mortem examination were reviewed. Clinical records were
evaluated for information relating to the PEX therapy including
the specific dialysis catheter used, type of anticoagulant provided,
replacement fluids, each patient’s PEX prescription, number of
cycles, duration of cycles, requirements of additional transfusion
of blood products, complications and outcome.
Descriptive statistics are provided and where indicated, results
are reported as median (range).
RESULTS
Six dogs met the inclusion criteria during the study period.
There was one dog diagnosed with CRGV during the study
period which did not undergo PEX and was thus excluded. Two
dogs were female entire and 4 dogs were female neutered. The
median age was 4 years (10 months to 8 years) and median body
weight was 21.8 kg (range 11.2–27). Breeds represented included
2 Labradors Retrievers, 2 mixed breed dogs, 1 Cocker Spaniel and
1 Dalmatian.
Clinical Signs
All dogs were reported to have developed cutaneous lesions.
The length between observation of the cutaneous lesions and
admission to the primary veterinary surgeon was 6 days (range 1–
9); 5/6 dogs were reported to have progressive lameness and a stiff
gait. Other presenting complaints included lethargy (n = 3, case
2, 4, 6), inappetence (n = 3, case 2, 3, 4), hemorrhagic diarrhea
(n= 2, case 4, 6) and vomiting (n= 1, case 6). All dogs had been
hospitalized for a median of 3 days (range 1–7) at the referring
practice prior to admission to our center.
Clinical signs were reported to have acute onset prior to
presentation to their primary veterinary surgeon and rapid
clinical deterioration was reported in all dogs.
At presentation, the abnormalities on physical examination
and initial assessment included cutaneous lesions, which were
mainly identified at the extremities [n = 6, respectively pelvic
limbs (n= 4, case 1, 2, 3, 4) and thoracic limbs (n= 2, case 5, 6)],
ventrum (n = 1, case 3), and on the head with both cutaneous
and oral lesions (n = 1, case 1). All dogs were normothermic at
time of admission [median 38.5◦C, (range 37.7–38.9◦C)].
Three dogs were tachycardic [case 1, 4, 5; respectively 148
(case 1) and 120 (case 4 and 5) beats per minute] at time of
presentation. These dogs were normotensive with evidence of
volume overload. In total 5/6 dogs had evidence of volume
overload. Volume overload was identified as weight gain in
comparison to the weight reported in the history when healthy
(n = 5), the presence of cutaneous edema (n = 3) or cavitary
effusion identified with ultrasonography (n = 4, 3 dogs had
peritoneal effusion and 1 dog had both pleural and peritoneal
effusion). All six dogs were either oliguric (n = 3, cases 4, 5, 6)
or anuric (n = 3, cases 1, 2, 3) at the time of referral. Four dogs
were hypertensive using criteria established by Brown et al. (20)
at time of presentation, diagnosed using the Doppler technique
(cases 2, 3, 4, 5; respectively 225, 252, 180 and 170 mmHg).
Clinicopathological Findings
Clinicopathological findings for all dogs are summarized in
Tables 1, 2. Serum biochemistry demonstrated that all dogs were
azotemic [creatinine 301 µmol/L, 144–676 µmol/L (reference
interval (RI) 59–138 µmol/L); urea 35.9 mmol/L, 13.2–72.6
mmol/L (RI 3–9.1 mmol/L)] and hyperbilirubinemic [4.85
µmol/L, 3.4–96.7 µmol/L (RI 0–2.4 µmol/L)] and that 5 dogs
were hypoalbuminemic [22.1 g/L; 19.7–23.4 g/L (RI 28–39 g/L);
Table 1]. Dogs were graded according to the International Renal
Interest Society (IRIS) AKI grading system (21): Grade III
(n = 4), Grade IV (n = 1), Grade V (n = 1) during the first
24–48 h of hospitalization. During the time of hospitalization,
the median peak concentration of creatinine was 693.5 µmol/L
(range 509–1199), which corresponded to progression to IRIS
AKI grade IV (n = 5) and V (n = 1). The lowest concentration
of albumin measured during hospitalization was 19.85 g/L (range
10–22.7).
Hematology revealed a non-regenerative anemia in 4
dogs [median PCV 26%, range 26–33% (RI 37–55%)] and
thrombocytopenia in all dogs [median estimated manual platelet
count was 75 × 109/L (range 15–80 × 109/L) (RI 150–190
× 109/L); see Table 2]. None of the patients had received
any previous blood product transfusion. Standard coagulation
profile including activated partial thromboplastin time and
prothrombin time were within reference intervals in all the five
dogs in which they were tested. One of the six dogs did not have
a standard coagulation profile performed (see Table 1).
Urine analysis (n = 6) showed a median urine specific gravity
of 1.015 [range 1.009–1.021 (RI 1.018–1.050)], with varying
degrees of proteinuria (1+, case 5; 2+, case 4 and 6; 3+, case
1, 2, 3). Granular casts were documented in 3/6 dogs (cases
1, 5, 6). Four of six dogs (case 1, 3, 5, 6) had an evaluation
of UPC ratios performed, with a median of 2.95 [range 0.49–
11.16 (RI < 0.5)]; of these only one dog had an inactive
urine sediment analysis with low cellularity. Urine culture was
performed in 4/6 dogs. The collection of urine via cystocentesis
for bacterial culture was deemed contraindicated in two dogs
due to severe thrombocytopenia. A urinary tract infection was
diagnosed in 1 dog (case 1); this was suspected to be hospital-
acquired following urinary catheterization and the following
organisms were cultured: Escherichia coli, Enterococcus spp., and
Staphylococcus aureus. This dog, at time of presentation, had a
negative urine culture prior to urinary catheterization. When the
diagnosis of a urinary tract infection was made following repeat
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TABLE 1 | Admission serum biochemical and coagulation times for six dogs with cutaneous and renal glomerular vasculopathy at the tertiary referral center.
Reference interval MEDIAN IQR Q1 Q3 Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Total protein 49–71 g/L 44.6 17 38.78 51.05 34.2 44.6 44.2 47.9 40.3 60.5
Albumin 28–39 g/L 21.40 7 20.23 25.15 19.7 20.4 22.7 23.4 21.4 30.4
Globulin 21–41 g/L 24.2 11 17.8 25.9 14.5 24.2 21.5 24.5 18.9 30.1
Sodium 142–153 mmol/L 147.0 3 146.75 152.25 148 146 156 147 151 147
Potassium 3.9–5.5 mmol/L 4.5 1 4.08 5.18 4.1 4.6 5.1 4 5.4 4.5
Chloride 105–118 mmol/L 112.0 11 108.25 115.75 121 112 114 110 113 103
Calcium 2.13–2.7 mmol/L 2.35 1 2.01 2.4 2.36 2.13 2.14 2.35 2.53 1.66
Inorganic Phosphorus 0.8–2 mmol/L 3.13 2 2.39 4.1 3.13 1.92 3.31 5.07 3.77 2.55
Urea 3–9.1 mmol/L 37.5 31 21.08 46.43 37.7 13.2 23.7 72.6 37.5 34.2
Creatinine 59–138 µmol/L 375 363 185.25 484 375 144 199 676 420 227
Cholesterol 3.3–8.9 mmol/L 4.5 1 4.13 6.35 4.2 4.5 6.8 4.7 3.9 6.2
Total Bilirubin 0–2.4 µmol/L 5.6 56 3.4 41.58 3.4 5.6 3.4 23.2 4.1 96.7
Amylase 176–1,245 U/L 1212 1290 846 1,829.75 949 1188 537 3416 1301 1212
Lipase 72–1,115 U/L 299 1728 107.75 1,118.25 152 101 110 3327 299 382
ALT 13–88 U/L 45 327 40.75 275.75 41 40 125 45 184 551
ALP 19–285 U/L 101 187 80.5 214.25 43 101 110 93 174 335
Creatine kinase 61–394 U/L 259 1100 226.25 1070.25 259 179 260 1791 830 242
Prothrombin time 7.5–9.9 (11–17) s 11.3 3 9.8 13 8.5 12 14 11.3 11.1
Activated Thromboplastin time 11–21 (72–102) s 16.3 108 13.9 122 13.8 109 135 16.3 14
The parameters outside the reference range have been highlighted in bold for six dogs with cutaneous and renal glomerular vasculopathy at the tertiary referral center.
urine analysis the antibiotic therapy was selected based on culture
and sensitivity test results.
Testing for Anaplasma phagocytophilum, A. platys, Borrelia
burgdorferi, Ehrlichia canis and E. ewingii antibodies and
Dirofilaria immitis antigens was negative in the two dogs (case
2 and 6) tested by using SNAP 4DX. Leptospirosis testing was
performed in all six dogs via MAT. Two dogs were also tested
using urine PCR (case 2 and 4). Four dogs (case 1, 2, 3, 5)
had Leptospirosis titers between 1:100 and 1:200, which are not
suggestive of active infection and in the remaining two dogs all
titers were negative (case 4 and 6) (22); rising titer MAT testing
was not performed in any dog.
Histopathological evaluation of skin biopsies in all dogs
revealed necroulcerative dermatitis with vasculitis and
thrombosis. The main findings included extensive dermal
ulceration with necrotizing folliculitis and perifolliculitis, and
adnexal necrosis with occasional vasculitis. The lesions were
largely centered to the hair follicles and adnexa. Two dogs (case
1 and 2) had a skin culture taken which revealed a growth of
Escherichia coli, Staphylococcus pseudointermedius, Streptococcus
canis, and Pseudomonas aeruginosa.
Diagnostic Imaging
Assessment for the presence of peritoneal effusion was performed
by point-of-care ultrasound and peritoneal effusion was present
in 4/6 dogs (cases 2, 3, 4, 5) which included presence of fluids in
1–2 out of 4 quadrants of the abdomen. A complete abdominal
ultrasound was performed in all dogs. In 4/6 dogs (case 1, 3, 4,
5) an enlarged and edematous pancreas with mixed echogenicity
was detected. One of these dogs (case 5) also had gallbladder
wall edema reported. One dog (case 6) had a thickened gastric
wall with loss of layering, likely due to inflammation. One
dog (case 6) had changes to the descending colon, consistent
with ongoing diarrhea and possible colonic ulceration, with a
maintained intestinal wall layering and normal thickness. One
dog (case 5) had a 3.5mm cortical nephrolith detected in the right
kidney, otherwise no ultrasonographic changes were reported in
the kidneys of other dogs.
Thoracic radiography was performed in all dogs following
placement of the dialysis catheter, with no abnormalities reported
on intrathoracic structures. There was only 1 dog (case 5) that
had a scant pleural effusion present at time of arrival on point-
of-care ultrasound of thorax. Three dogs had echocardiographic
assessment by a board-certified cardiologist (cases 2, 4, 5): one
dog (case 5) had signs of aortic insufficiency and one dog (case
2) had a mild depression of systolic function and dilatation of the
left ventricle.
Medical Management
Medical management from time of admission to the hospital
prior to PEX therapy varied. Only one of the six dogs (case
6) received intravenous fluid therapy (Aquapharm 11 R©), at
time of admission due the presence of clinical dehydration. All
dogs received antimicrobials in the event the pathogenesis was
related to an infectious cause. The following antimicrobials were
administered: potentiated amoxicillin (Augmentin R©) (n = 5
case 1, 2, 3, 4, 6), doxycycline (Ronaxan R©) (n = 2, case
1, 2), marbofloxacin (Marbocare R©) (n = 1, case 3), generic
ampicillin (Ampicillin R©) (n = 1, case 5), generic cefuroxime
(Cefuroxime R©, case 5) and generic cephalexin (RilexineTM)
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TABLE 2 | Hematology analysis performed on admission in six dogs with cutaneous and renal glomerular vasculopathy at the tertiary referral center.
Reference Interval Median IQR Q1 Q3 Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
RBC 5.5–8.5 1012/L 4.25 3 3.9 6.57 3.95 3.9 6.33 3.9 4.55 7.3
HCT 37–55% 31.6 24 27.18 51.23 28.1 27.1 50.9 27.2 35.1 52.2
PCV 37–55% 29.5 26 26 51.75 26 26 51 26 33 54
Hgb 12–18 g/dL 10.7 8 9.25 16.88 9.1 9.3 16.3 9.7 11.7 18.6
MCV 60–77 fL 71.4 8 69.65 78 71.3 69.5 80.4 69.7 77.2 71.5
MCH 19.5–24.5 pg 25.15 2 23.7 25.73 23.1 23.9 25.8 24.8 25.7 25.5
MCHC 32–36 g/dL 33.8 3 32.33 35.63 32.4 34.3 32.1 35.6 33.3 35.7
RDW % 12.8 2 11.93 13.78 13.6 12.7 11.7 14.3 12.9 12
WBC 6–17 109/L 13.12 6 12.02 17.68 13 14.29 12.8 13.23 27.86 9.69
Neutrophils 3–11.5 109/L 10.2 7 7.62 14.97 9.9 12 10.5 6.62 23.86 7.95
Neutrophils % 82 15 69.5 84.25 76 84 82 50 85 82
Lymphocytes 1–4.8 109/L 1.69 2 1.03 2.84 1.95 1.43 1.28 3.84 2.51 0.29
Lymphocytes % 10 11 7.5 18.5 15 10 10 29 9 3
Monocytes 0.15–1.5 109/L 1.18 1 0.76 1.92 0.78 0.71 0.9 2.65 1.67 1.45
Monocytes % 6.5 11 5.75 16.25 6 5 7 20 6 15
Eosinophils 0–1.3 109/L 0.13 0.2 0 0.2 0.39 0.14 0.13 0.13 0 0
Eosinophils % 1 1.5 0 1.5 3 1 1 1 0 0
Basophils 0 0 0 0 0 0 0 0 0
Basophils % 0 0 0 0 0 0 0 0
Platelets 150–900 109/L 80 66.2 26.25 92.5 80 80 80 15 >130 30
RBC, Red Blood Cells; HCT, Hematocrit; PCV, Packed Cell Volume; Hgb, Hemoglobin; MCV, Mean Corpuscolar Volume; MCH, Mean Corpuscolar Hemoglobin; MCHC, Mean
Corpuscolar Hemoglobin Concentration; RDW, Red blood cell Distribution Width; WBC, White Blood Cells. The parameters outside the reference range have been highlighted in
bold.
(n = 1, case 1). All dogs also received antiemetic therapy:
maropitant (Cerenia R©) (n = 6), metoclopramide (Emeprid R©)
(n = 5, case 1, 3, 4, 5, 6) and generic ondansetron
(Ondansetron R©) (n = 5, case 1, 2, 4, 5, 6). All six dogs
received a proton pump inhibitor (Omeprazole R©). Further
medical management consisted of amlodipine (Amodip R©)
(n = 5, case 1, 2, 3, 4, 5) and pentoxifylline (Trental R©, case
1, 2, 3, 5) (n = 4). Pentoxifylline was administered as a
potential adjunctive treatment for the presumed presence of
vasculitis. One dog (case 4) required anti-seizure medication
with diazepam (Diazemuls R©) and levetiracetam (Keppra R©).
Analgesia was required in 5/6 dogs: methadone (Synthadon R©)
(4/5 case 1, 3, 4, 5, 6) and buprenorphine (Buprecare R©) (1/5,
case 2).
Within the first 24 h of monitoring urine output (UOP), four
dogs (case 1, 2, 3, 5) received furosemide (Dimazon R©) either as
a bolus or constant rate infusion in the attempt to improve urine
production. Urinary output was quantified using an indwelling
urinary catheter and a closed collection system in 4/6 dogs (cases
1, 2, 3, 5) and estimated through monitoring of body weight and
assessment of fluid balance by assessing presence of cutaneous
edema and cavitary effusions in all dogs. Prior to initiation of
diuretic therapy, UOP measured in 4 dogs was 0, 0.25, 0.3, and
0.5 mL/kg/h. After initiation of diuretics the UOP increased to
1.55, 2.81, 2.87, and 3.64 mL/kg/h. This was the UOP measured
during hospitalization at the time of PEX therapy. The two dogs
without initial urinary catheterization were oliguric withminimal
urination prior to first PEX cycle, and both dogs had a urinary
catheter placed at the time of PEX. One of these dogs (case
6) was clinically dehydrated and received fluid therapy which
resulted in polyuria with a median UOP 7.4 mL/kg/h (range 5.5–
17.9 mL/kg/h) on day 2 of hospitalization. Another dog (case 2)
became polyuric over a short period of time after initiation of
diuretics.
Advanced Medical Management–Plasma
Exchange
The decision to perform plasma exchange was made within
24–48 h of hospitalization due to lack of clinical improvement,
worsening azotemia and persistent oliguria or anuria despite
advanced medical management as described.
Three dogs (case 1, 3, 4) underwent one PEX cycle and
two of these dogs (case 3 and 4) also required a cycle of
prolonged intermittent renal replacement treatment (PIRRT)
with veno-venous hemodiafiltration to treat the severe azotemia
and hyperkalemia the following day. The duration of PIRRT
treatment was respectively 5 and 6.5 h, which resulted in a
urea reduction ratio (URR) of 45.6 and 56%, respectively. The
three other dogs (case 2, 5, 6) underwent two cycles of PEX
within 48–72 h. Only case 1 received a single cycle of PEX, the
remaining 4 dogs received two extracorporeal therapy cycles
each (see Table 3). The PEX cycles were performed using an
extracorporeal plasmafiltration system (Prismaflex R© Software
version 6.XX, Prismaflex R© TPE 2000 with a 125mL blood
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TABLE 3 | Summary of the plasma exchange therapy in six dogs with cutaneous and renal glomerular vasculopathy at the tertiary referral center.
Median IQR Q1 Q3 Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Body Weight (Kg) 21.3 14 13.85 27.75 25.7 27.7 10.4 16.8 27.9 15
Number of PEX cycles 1.5 1 1 2 1 2 1 1 2 2
Duration of cycles (Hours) 3 1 2 3.25 3 3 2.5 3.5 4 3 2 2 2
PV Exchanged (ml) 1,440 957 898.5 1,667.5 1,710 1,688 1,647 495 1,249 1,631 1,426 817 980
Achieved PV exchange 1.9 1 1.45 2.38 2 1.8 1 3.3 2.5 1.6 1.8 1.4
Kg, Kilogram; PV, Plasma Volume.
FIGURE 1 | Patient undergoing a plasma exchange (PEX) cycle. Permission
for publication of this image was obtained by the clients. In the background,
the extracorporeal plasma filtration unit can be seen (Prismaflex®;Gambro).
volume per set) and the PIRRTwas performed using Prismaflex R©
Software version 6.XX, Prismaflex R©; Prismasol R©4; Gambro, UK)
(see Figures 1, 2).
Vascular access was achieved in all dogs by placement
of a short-term, double lumen, dialysis catheter (CovidenTM,
MahurkarTM; Acute Dual Lumen Catheter Kit) in the jugular
vein. The chosen size of the jugular catheter was based on the
size of each dog, ranging from 11.5–13.5 Fr to 19–24 cm. Four
dogs had the catheter placed in the right jugular vein and two
dogs in the left jugular vein. The procedure was performed
under general anesthesia using surgical aseptic conditions with
modified Seldinger technique used. Anticoagulation for the
PEX cycles was achieved with regional anticoagulation, infusing
Citrate ACD-A (Haemonetics R©) through the pre-blood pump in
all 6 dogs.
Our citrate protocol consisted of administering Citrate ACD-
A at a rate of 5.65 mmol citrate per liter of circulating blood for
30min. Following this we aimed to reduce the citrate infusion to
1.69–2.26 mmol/L of blood. The citrate infusion was titrated to
achieve an extracorporeal plasma ionized calcium concentration
of <0.35 mmol/L. Calcium gluconate (Calcium gluconate 10%)
was administered diluted to 2.4% with NaCl 0.9% (Aquapharm
1 R©) at a starting rate (ml/h) of 0.4 times the citrate infusion
FIGURE 2 | The extracorporeal plasma filtration system can be seen
(Prismaflex® TPE 2000; Gambro).
(ml/h) and subsequently titrated to achieve a target plasma
ionized calcium in the patient between 1.1 and 1.3 mmol/L (23).
The median Plasma Volume (PV) exchanged with PEX was
1.8 (range 1–3.3) with a median volume of 1426mL (range 495–
2,565mL). The PV was calculated by the following equation;
PV = (BW(kg) × 0.09) × (1-hematocrit) (16, 24). PEX was
performed over a median time of 3 h (range 2.5–4) (see Table 3).
Plasma removed was replaced with a combination of 0.9% saline
(Aquapharm 1 R©) and stored (SFP) or fresh frozen plasma (FFP).
For each cycle, the replacement fluid initially used was 0.9%
sodium chloride before transitioning to FFP/SFP infusion. The
median time before transitioning to plasma was 70min (range
25–120). The plasma prescribed was blood-type matched for
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each recipient. Plasma administered accounted for 30.4% (range
16.3–48.8) of the total volume exchanged.
Complications observed during plasma exchange included
hypocalcemia, hypothermia, sinus tachycardia and hypotension.
All dogs developed hypocalcemia (median ionized calcium 0.68
mmol/L (range 0.55–0.86)). However, only one patient (case
6) developed clinical signs attributable to hypocalcemia, with
facial twitching which resolved with an additional 1 mL/kg IV
bolus of 10 % calcium gluconate. Hypothermia (<37◦C) was
identified in 4 dogs despite the use of active heating with forced
air heating blankets from the outset (Bair Hugger model 505;
Augustine Medical), and the use of a blood warmer on the
extracorporeal circuit return line immediately after connection.
Sinus tachycardia (heart rates of 189 and 190 beats per minute,
respectively) was observed in 2 patients (case 3 and 6).
Two dogs (case 3 and 6) developed severe hypotension
(Doppler systolic pressure 60mmHg), one during a cycle of
PEX and the other during a cycle of PIRRT. Case 6 developed
hypotension during her first PEX cycle due to hypovolemia from
bleeding from venipuncture and the catheter insertion sites. This
patient was severely thrombocytopenic. The hypotension did not
respond to fluid resuscitation [45 mL/kg bolus of Hartmann’s
Solution (Aquapharm 11 R©)] and required vasopressor therapy
with a noradrenaline (Norepinephrine R©) constant rate infusion.
Later in the same PEX cycle, this patient developed neurological
signs (obtundation and nystagmus) at the end of treatment
cycle requiring interruption of PEX and the return of the
extracorporeal blood to the patient. Due to ongoing bleeding this
patient was further stabilized with a transfusion of packed red
blood cells (pRBC).
The second dog (case 3) developed hypotension during her
PIRRT cycle which did not respond to fluid resuscitation, also
requiring noradrenaline constant rate infusion. This patient
later developed neurological signs (mitotic pupils and loss of
muscle tone) which was stabilized with a bolus of hypertonic
saline (Braun Vetcare hypertonic NaCl solution 7.5% R©) and
interruption of PIRRT. Following the return of extracorporeal
blood to the patient and hypertonic saline administration,
this patient regained consciousness and became normotensive.
Median blood pressure in all dogs during PEX was 140mmHg
(range 60–220). Two dogs (case 4 and 6) required additional
blood transfusions with pRBC. The PEX therapy was performed
the day following admission at our center in 4/6 dogs (case 2, 4,
5, and 6) and on day 2 of hospitalization in 2/6 dogs.
Outcome
Median length of hospitalization until either discharge from
hospital or time of death was 5.5 days (range 4–23 days). Four
dogs (case 3, 4, 5, 6) were euthanized at the owners’ request due to
lack of clinical improvement, ongoing costs and grave prognosis.
A post-mortem examination was performed in all non-surviving
dogs and the results were characteristic of CRGV as described by
Holm et al. (5), with renal glomerular and tubular necrosis and
vessel occlusion with thrombi.
Of the 4 non-survivors (case 3, 4, 5, and 6), median
time to euthanasia was 5 days (4–6 days). Case 3 continued
with severe clinical deterioration despite repeat cycles with
both PEX and PIRRT. Her clinical deterioration consisted of
obtundation, worsening azotemia, marked pelvic limb vasculitis
with the concern that she would not tolerate the required
PIRRT cycles for management of her AKI. Therefore, the
owner elected euthanasia. Case 4 was euthanized due to
neurological deterioration with ongoing seizure activity; post-
mortem examination showed multifocal neuronal degeneration
and necrosis with hemorrhage and edema. Case 5 developed
septic shock and hypoxemia; post-mortem examination revealed
the presence of severe pneumonia and bacterial endocarditis.
This patient had a sudden clinical deterioration following the
second PEX cycle, which was performed 48 h after placement
of the dialysis catheter. Echocardiography in this patient was
performed prior to catheter placement and did not reveal
any signs of endocarditis or systolic dysfunction. Case 6
was euthanized due to sudden development of respiratory
failure requiring further life-support withmechanical ventilation;
heart failure and volume overload were excluded based
on physical examination, patient-side echocardiography and
thoracic radiographs. The owners elected euthanasia and a cause
for the respiratory distress was not identified despite post-
mortem examination. There were no significant pathological
changes on histological examination of the heart and lungs of this
patient.
Two dogs (case 1 and 2) survived to discharge from hospital.
The survivors were hospitalized for 10 and 23 days, respectively.
During hospitalization both dogs were hypertensive and anuric.
Case 1 received 1 PEX cycle, and case 2 received 2 PEX cycles
without major complications. One of the survivors (case 2)
became polyuric after starting diuretic therapy. The patient
remained polyuric throughout its single PEX cycle and was
weaned off diuretics 19 h post PEX. At the time of discharge, case
1 had mild azotemia (creatinine 202 µmol/L, urea 18.3 mmol/L)
and hyperphosphatemia (2.11 mmol/L, RI 0.8–1.6 mmol/L).
This was an improvement compared with pre-treatment values
[creatinine 760 µmol/L (RI 59–138 µmol/L), urea 55.1 mmol/L
(RI 3–9.1 mmol/L) and phosphorus 3.68 mmol/L (RI 0.8–1.6
mmol/L)]. The second survivor (case 2) also had mild azotemia
at time of discharge (creatinine 257 µmol/L, urea 17.2 mmol/L,
and a normal phosphorus 1.92 mmol/L) compared to a moderate
azotemia while hospitalized (creatinine 351 µmol/L, urea 30.1
mmol/L and phosphorus 3.64 mmol/L). These dogs were still
alive at the time of last follow up 3 years and 2 months (case
1) and 1 year and 9 months (case 2), respectively after discharge
from hospital. By that time, the dogs were doing well clinically
with no requirements for further medical management. The
azotemia had completely resolved for case 1, whilst case 2 had
a slightly increased urea (9.2 mmol/L) but a normal creatinine
concentration (101 µmol/L). Both cases were normotensive and
were considered as IRIS Chronic Kidney Disease stage 1 (21).
During hospitalization, they both had and IRIS grade III AKI.
DISCUSSION
This study describes the use of PEX in 6 dogs clinically
diagnosed with CRGV. Unfortunately, only 2/6 dogs survived
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to discharge. Overall, PEX was tolerated by dogs; however,
commonly reported complications of apheresis therapy were
identified. Current human recommendations for the treatment
of TMA would be to perform daily cycles for three days, though
this approach does not have strong evidence base (11). The
decision to perform a further treatment with a cycle of PEX
or PIRRT 24–48 h later was made following consideration of
patient stability, clinical progression and patient- and owner-
related factors, including financial considerations. Ultimately,
the role that PEX played in either the reduced progression or
recovery in the two surviving dogs cannot be ascertained from
this study. The two survivors appeared to respond to cycles
of PEX therapy as they became less clinically affected with
no development of neurological abnormalities compared to the
non-survivors. Given the potential of similarities in etiology
for TMA between dogs and people and the high mortality rate
reported in dogs with CRGV, PEX could be considered a viable
modality of therapy in these dogs, although further research is
warranted.
Thrombotic microangiopathy in people can occur secondary
to several causes, including TTP and HUS. A detailed review
of the causes of TMA in people is beyond the scope of
this study and readers are referred elsewhere (1, 6, 7). In
brief, TTP is a hypercoagulable state, caused by inhibition
of ADAMTS-13, a factor-cleaving protease, by auto-antibodies
which leads to a lack of degradation of von Willebrand factor
multimers. VonWillebrand factor multimers are prothrombotic,
thus ADAMTS13 inhibition leads to microthrombi formation,
microangiopathic hemolytic anemia, thrombocytopenia and
multiple organ injury, including renal injury (24). In people with
TTP, PEX has demonstrated to substantially increase survival
from 10 to 78% and is now considered a first-line treatment, even
in cases with uncertain diagnosis (1, 8).
Hemolytic Uremic Syndrome, on the other hand, can be
caused by detectable underlying factors, such as Shiga toxin-
producing E. Coli or drugs (e.g., quinine or calcineurin
inhibitors) (1). Management in these cases consists of addressing
the trigger for the condition when known. The term aHUS
describes a condition typically seen in pediatric patients,
characterized by TMA (microangiopathic hemolytic anemia,
thrombocytopenia and renal failure) but without the prodromic
hemorrhagic diarrhea (25). Atypical HUS seems to be caused
by complement-mediated microangiopathy, resulting from an
uncontrolled activation of the alternative complement pathway
(1, 26); the main clinical feature is kidney failure (1, 8). Anti-
complement therapy has been recently shown to be the most
effective therapy in these patients. However, the cost of the
treatment is prohibitive for veterinary patients (25, 27). For both
these conditions, PEX is considered a standard treatment and has
been shown to reduce mortality (1, 8, 26, 28).
Therefore, the major goals of PEX in TTP are the
removal of the antibodies against ADAMTS-13 and the
supplementation of ADAMTS-13 via FFP, preventing further
thrombi formation. Similarly, in aHUS PEX can remove the
aberrant complement and provide replacement with normal
complement factors (28). In people with TMA, PEX with FFP
has shown a reduction in mortality compared to single plasma
infusion alone (7, 29). Because of the high mortality rate
associated with TTP, PEX is often initiated in the presence
of an unexplained thrombocytopenia and anemia secondary to
suspected microangiopathic disease even before confirmation of
this condition (7).
In dogs, reported causes for TMA include HUS (30) and
CRGV (2–5), with the latter being first reported in the USA
in 1988 and initially referred to as “Alabama Rot” (2, 3).
In the outbreaks reported in the USA, most of the dogs
affected were greyhounds who developed a variable degree of
the disease, including cutaneous lesions, localized specifically
to the limbs, and AKI. Not all dogs developed AKI and some
patients developed AKI before the cutaneous lesions could be
identified, making the clinical presentation heterogeneous (2).
It is unclear whether the previously reported “Alabama Rot”
represents the same disease as the CRGV that is affecting dogs
in the United Kingdom or whether a different etiopathogenesis
exists. Possible differential diagnoses for the underlying cause of
AKI include Leptospirosis which can be tested for by serology,
PCR and histopathology of renal and hepatic tissue (5). Not
all clinical presenting features in patients with leptospirosis are
comparable with the presentation of CRGV cases (e.g., skin
lesions are not normally reported with leptospirosis). Another
differential could include an adverse drug reaction causing skin
lesions and multiple organ dysfunction syndrome. However,
CRGV cases develop skin lesions first and typically have not had
any exposure to drugs until after these lesions appear. Another
known cause leading to TMA in dogs other than CRGV is
HUS, though skin lesions have previously never been reported
in canine HUS. In human HUS, the most commonly reported
forms are caused by E. coli or Shigella dysenteriae Shiga toxin
or by Salmonella or Campylobacter infections, which can be
identified by fecal culture (5). To the authors’ knowledge, there
appears to be no other obvious differential diagnosis for the
combination of clinical signs in the cases presented in this study.
No underlying causative agent has been identified in dogs with
CRGV despite a detailed investigation that included the search
for immune-complex deposition, viral (canine circovirus) or
bacterial disease presence (Shiga toxin, E.coli, Leptospira) (2, 3, 5)
albeit performed in relatively small numbers of cases and with
the caveat that chronology may be of importance in terms of
sampling and identifying these factors. Other causes, such as
ADAMTS-13 deficiency, complement-activation or detection of
toxins responsible for TMA in people have not been investigated
thus far.
All patients described in this study developed cutaneous
lesions, with evidence of microangiopathic damage,
thrombocytopenia and AKI with 4/6 dogs also developing
anemia. Renal biopsy was available for confirmation of CRGV in
4/6 dogs. In the remaining 2 dogs clinicopathological features,
combined with compatible dermal histopathology, strongly
indicated that CRGV was the underlying disease process despite
the lack of renal biopsies. Definitive ante-mortem confirmation
of TMA in the 2 surviving dogs would have required renal biopsy,
but the risk of potential bleeding in the face of thrombocytopenia
was considered to outweigh the benefit of confirming the
diagnosis.
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At the time of manuscript preparation, no treatment has been
demonstrated to reduce the high mortality associated with this
disease in dogs developing oliguric or anuric AKI (5). The cases
described in this report presented with anuric or oliguric AKI and
rapidly deteriorating conditions that failed to respond to medical
treatment. Thus, due to the similarity of clinical progression and
clinic-pathological abnormalities resembling either TTP or aHUS
in people, we postulated that PEX would be a reasonable method
of treating these cases.
The decision to perform PEX in the dogs included in this
study was made when there was an apparent progression of their
CRGV syndrome, with the aim of intervening early to achieve
removal of suspected immune complexes that could be involved
in the pathophysiological mechanism of CRGV. Nevertheless,
the patients included in this study were already at an advanced
stage in the disease process on the basis that they presented
with azotemia and oligoanuria. The optimal time to intervene
with therapies such as PEX has not been established. However,
from clinical experience, intervention after the development of
severe AKI appears to be associated with a guarded prognosis.
This raises questions as to whether the most appropriate time
to intervene with therapies such as PEX is at the time point
when non-azotemic AKI is identified or UOP first begins to
fall. However, lack of a definitive diagnostic test, other than
renal biopsy, the intense and invasive nature of PEX therapy
that is not without the potential for complications, makes this a
challenging judgment call to make, particularly considering that
based on clinical experience some of the less severely affected
but clinically suspected cases may show improvement with
standard management for AKI. In light of the poor prognosis
associated with this condition, once AKI and oliguria develop, we
considered PEX to be the best alternative to manage this disease
as long-term dialytic therapy was not a clinically or financially
viable option for these dogs currently in the UK. These cases
were particularly severely affected. It is possible that patients with
CRGV can present with a spectrum of clinical signs, some of
which may be azotemic and managed in primary care practice
recovering with supportive treatment and not reaching the level
of severity of the disease of those cases that make it to referral
practice.
The role that PEX played in the positive outcome of 2 of
the 6 cases is difficult to ascertain and represents a major
limitation of this report. It is possible that these patients would
have improved in terms of their clinical status with continued
supportive therapy, particularly given that there was indication
of improved UOP after furosemide administration in one of
the surviving cases. As previously reported, a positive response
in UOP following furosemide administration in patients with
AKI may reflect less severe renal injury (31). Nevertheless, the
potential utility of this modality of therapy for this indication
requires further investigation. In light of the fact that patients
with CRGV and oliguric AKI have such a poor prognosis, the
positive outcome in the two cases presented is of interest.
All of the 4 non-survivors (case 3, 4, 5, and 6) were euthanized
at their owner’s request within the first week of hospitalization
and often requested the day following a PEX cycle. There
were various reasons for the decision for euthanasia including
clinical deterioration, grave prognosis and costs. All owners
were aware of the timeframes expected for renal recovery, the
need of repeat cycles as well as the financial investment these
advanced therapeutic options require from the outset. Given the
complexity of these cases, various factors may have influenced
some of the clients to request humane euthanasia instead of
continuing with management early in the course of the disease.
Extracorporeal therapy requires specially trained staff, clinical
expertise and special equipment. PEX is not a risk-free therapy,
but studies in people have shown that there can be improved
survival rates with the use of PEX in TMA patients (10) and
that adverse effects associated with PEX have been reported to be
<10% (27). Some form of quantitative evaluation of the efficacy
of PEX therapy would have been useful to assess response to
therapy in individual patients. Future studies, should focus on
whether systemic markers of inflammation could be used for
these purposes, for example C-reactive protein.
The complications associated with PEX observed in the
current study are similar to those previously reported, such as
hypotension and citrate-induced hypocalcemia (12–18). Other
complications of extracorporeal therapies previously reported
such as hypersensitivity reaction to replacement fluids (16) were
not observed in our study. One of the non-survivors (case 5)
developed septic shock and hypoxemia following her second
PEX cycle; post-mortem examination revealed the presence of
bacterial endocarditis and pneumonia. It is unclear whether a
catheter-related infection or aspiration were the cause of the
rapid deterioration. The owners elected euthanasia following the
development of this deterioration. The other 3 non-survivors
(case 3, 4, and 6) did not have any documented complications
after the PEX therapy. Case 3 and 6 both developed severe
hypotension during a PIRRT cycle (URR 45.6%) and PEX
cycle (1.8 PV exchanged), respectively. They were the two
smallest dogs in this population (10.4 and 15 kg, respectively)
and it is hypothesized that hypovolemia contributed to the
reported hypotension. Both the rate of extracorporeal therapy
and size of extracorporeal circuit used may have contributed
to hypovolemia. In particular, case 6 was successfully weaned
off vasopressors after returning blood from the extracorporeal
circuit and transfusion of a unit of pRBC suggesting that
hypovolemia may well have been a significant contribution to
the hypotension. The neurological signs case 6 experienced were
likely caused by reasons other than an ischemic insult due to
rapid improvement following stabilization. Case 3 also clinically
improved at time of ending cycle and returning blood to patient
with improvement of perfusions parameters.
Previous studies have reported that glomerular disease often
leads to a UPC ratio >2.0 in dogs (32). Renal loss of albumin
can lead to hypoalbuminemia which was seen in 5/6 dogs in our
study. Moreover, as albumin is a negative acute phase protein,
the inflammatory nature of this disease could have contributed
further to decreased albumin concentration. As albumin is the
main determining factor of colloid oncotic pressure, marked
decreases in albumin concentration could negatively impact
fluid distribution between body compartments (32). The dogs
in the present study had marked proteinuria, median UPC ratio
of 2.95 (range 0.49–11.16) with hypoalbuminemia reported in
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5/6 dogs. The albumin concentrations of the two dogs that
demonstrated hypotension were 18.6 g/L for case 3 and 30.4
g/L for case 6, respectively. These values were not deemed
severe enough to cause reduced oncotic pressure and therefore
it is unlikely that in either of these patients hypotension was
the result of third spacing due to hypoalbuminemia. Both
dogs responded well to medical management with vasopressor
therapy (noradrenaline). Case 6 also developed clinical signs
of hypocalcemia (facial twitching) with an ionized calcium
of 0.67 mmol/L (RI 1.13–1.33 mmol/L) which responded to
calcium gluconate supplementation. The hypotension was only
experienced in PEX cycle one; for the second cycle we decreased
the calculated PV from previous 1.8–1.4 which was tolerated
well. This patient was later euthanized at the owner’s request
due to clinical deterioration and onset of respiratory distress.
Case 3 which developed hypotension during PIRRT was later
euthanized at the owner’s request due to a combination of
welfare issues, requirement for repeat cycles of PIRRT with
clinical deterioration, ongoing financial commitment and grave
prognosis for survival.
Two dogs (case 3 and 6) developed tachycardia during PEX
therapy. Case 6, as described above, became hypotensive possibly
secondary to hypovolemia which may explain the compensatory
tachycardia. However, case 3, was normotensive throughout
the PEX cycle and as such it seems unlikely that volume
changes contributed to tachycardia. Case 3 did, however, become
agitated and required additional sedation with opioid analgesia
and benzodiazepine constant rate infusion which improved the
tachycardia. As PEX therapy is an invasive procedure, this
requires patients to be calm during the cycle to allow good blood
flow and avoid catheter occlusion related issues.
In total, three dogs (case 3, 4, and 6) developed neurological
abnormalities. Case number 3 and 6 developed neurological
signs with abnormal mentation during PIRRT and PEX
therapy respectively due to hypovolemia. Case 4 already had
abnormal neurological signs prior to PEX with seizure activity
at the time of presentation. It is difficult to ascertain if
these were a consequence of the clinical progression of the
disease; neurological post-mortem examination was performed
in case 4 and documented evidence of CNS necrosis with
hemorrhages.
The current recommendation in human medicine regarding
PEX therapy is to perform 1–1.5 PV exchange during a cycle (11).
The extracorporeal unit (Prismaflex) calculates the exchanged
plasma volume and does not include the pre-blood pump
(citrate) flow rate in this volume. This led to a wide range
of PV exchanged (range 1–3.3) in the retrospective analysis.
In each case, initial PV calculations were performed for a 1–
1.5 PV exchange. Our median PV exchanged was 1.8 which
could have contributed to the complications experienced by our
patients. As discussed earlier our wide range of PV exchanged
includes the pre-blood pump. However, there are few conditions
in people where a large extracorporeal volume exchange
is recommended (e.g., immune-mediated thrombocytopenia,
overdose, envenomation and poisoning) (11).
The non-survivors that did not benefit from PEX may have
presented at later stages of the disease where renal function
was irreversibly compromised. In such patients, repeated cycles
of PEX combined with hemodialysis or PIRRT may have been
necessary in order to achieve a successful outcome. In people with
TMA, and specifically TTP, repeated cycles are often necessary
and recovery times often extend to weeks (1, 8, 33).
However, 3 out of 4 non-survivors (case 4, 5, 6) were
ultimately euthanized due to co-morbidities that occurred in
addition to their renal injury; namely neurological deterioration,
pneumonia/endocarditis and respiratory failure. It can be argued
that the number of cycles of PEX performed in the non-surviving
dogs was insufficient to allow appropriate renal recovery and/or
that these patients should have been supported with renal
replacement therapies e.g., hemodialysis in order to reduce
the morbidity. However, this was not possible in the patients
described in this study. In addition, in the cases reported, the
decision to perform euthanasia was not limited to renal recovery.
This study has some inherent limitations, such as the small
number of dogs included and the lack of a control group.
Holm et al. (5) retrospectively reviewed a population of dogs
with clinical signs consistent with CRGV and a confirmation
of TMA by renal histopathology. None of those dogs (n = 30)
received PEX as a therapeutic option but three dogs received
PIRRT. Sadly, all 30 dogs died or were euthanized. However,
Holm et al. (5) also report that they had clinical data in 6
surviving dogs with suspected CRGV, which responded well
to symptomatic management but that were excluded from
their study due to lack of confirmation of CRGV by renal
histopathology. The fact that dogs with CRGV present at
differing stages of their disease that vary in severity and that
the diagnosis can only be confirmed by performing an invasive
diagnostic test i.e., renal histopathology, severely limits our
ability to perform comparative clinical studies in dogs with
this disease. The development of a CRGV illness severity score
could help mitigate some of these challenges. For patients that
are not thrombocytopenic but where there is a high index of
suspicion for CRGV, renal biopsy may be considered in order
to confirm the diagnosis. It is difficult to ethically justify this
however, given that there are no known successful treatment
options other than supportive treatment for patients with
confirmed CRGV.
Future prospective randomized studies comparing dogs with
CRGV treated with and without PEX and stratified by illness
severity score would be needed to assess therapeutic efficacy.
Additional studies evaluating for the presence of autoantibodies
to ADAMTS13 in dogs with CRGV, as observed in people with
TTP, would also be recommended to clarify the pathogenesis of
this disease.
Another limitation regarding PEX therapy in this study
included the available fluids for replacement and the lack of
guidelines indicating the optimal timing of plasma infusion
initiation. Alternative fluids, such as synthetic colloids might
have been beneficial for these cases although concerns regarding
their safety is still unknown, especially in patients with AKI
(34). Nevertheless, we can only speculate that outcome may have
been different whether given more time or greater number of
treatment options either with PEX or PIRRT. The results of
renal histopathology in the four non-surviving dogs indicated a
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severe and disseminated disease, suggesting that chances of renal
recovery were likely to be limited.
CONCLUSIONS
In this retrospective study, we have described the novel
application of PEX as an adjunctive treatment in dogs with severe
CRGV. Plasma exchange is an invasive procedure, requiring
special equipment and specially-trained staff. However, the
good outcome in the two survivors, in light of the high
mortality reported with CRGV, warrants further consideration
whether PEX could prove helpful in selected cases. Moreover,
our finding should encourage further studies aimed at better
understanding the pathogenesis of this condition, and further
evaluation of the potential role of PEX in the treatment of affected
dogs.
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